<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2022-05-17">17 May 2022</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Klaus</forename><forename type="middle">H</forename><surname>Metzeler</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tobias</forename><surname>Herold</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maja</forename><surname>Rothenberg-Thurley</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Susanne</forename><surname>Amler</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Institute of Biostatistics and Clinical Research</orgName>
								<orgName type="institution">University of M ünster</orgName>
								<address>
									<addrLine>M ünster</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><forename type="middle">C</forename><surname>Sauerland</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Institute of Biostatistics and Clinical Research</orgName>
								<orgName type="institution">University of M ünster</orgName>
								<address>
									<addrLine>M ünster</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dennis</forename><forename type="middle">G</forename><surname>Örlich</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Institute of Biostatistics and Clinical Research</orgName>
								<orgName type="institution">University of M ünster</orgName>
								<address>
									<addrLine>M ünster</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephanie</forename><surname>Schneider</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nikola</forename><forename type="middle">P</forename><surname>Konstandin</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Annika</forename><surname>Dufour</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kathrin</forename><surname>Br</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bianka</forename><surname>Ksienzyk</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Evelyn</forename><surname>Zellmeier</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Luise</forename><surname>Hartmann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Philipp</forename><forename type="middle">A</forename><surname>Greif</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Fiegl</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marion</forename><surname>Subklewe</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><forename type="middle">K</forename><surname>Bohlander</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Molecular Medicine and Pathology</orgName>
								<orgName type="institution">University of Auckland</orgName>
								<address>
									<settlement>Auckland</settlement>
									<region>New Zealand</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Utz</forename><surname>Krug</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Internal Medicine 3</orgName>
								<orgName type="institution">Klinikum Leverkusen</orgName>
								<address>
									<settlement>Leverkusen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Faldum</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Institute of Biostatistics and Clinical Research</orgName>
								<orgName type="institution">University of M ünster</orgName>
								<address>
									<addrLine>M ünster</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolfgang</forename><forename type="middle">E</forename><surname>Berdel</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Medicine A, Hematology and Oncology</orgName>
								<orgName type="institution">University of M ünster</orgName>
								<address>
									<addrLine>M ünster</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bernhard</forename><forename type="middle">W</forename><surname>Örmann</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Tumor Immunology</orgName>
								<orgName type="institution">Charit é-Universit ätsmedizin Berlin</orgName>
								<address>
									<settlement>Hematology, Berlin</settlement>
									<region>Oncology</region>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolfgang</forename><surname>Hiddemann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Department of Medicine A, Hematology and Oncology</orgName>
								<orgName type="institution">University of M ünster</orgName>
								<address>
									<addrLine>M ünster</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Braess</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Oncology and Hematology</orgName>
								<address>
									<addrLine>Hospital Barmherzige Br üder</addrLine>
									<settlement>Regensburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Karsten</forename><surname>Spiekermann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="laboratory">Laboratory for Leukemia Diagnostics</orgName>
								<orgName type="institution">Ludwig-Maximilans-Universit ät</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="institution">American Society of Hematology</orgName>
								<address>
									<addrLine>December 6-9</addrLine>
									<postCode>2014</postCode>
									<settlement>San Francisco</settlement>
									<region>CA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="institution">American Society of Hematology</orgName>
								<address>
									<addrLine>December 5-8</addrLine>
									<postCode>2015</postCode>
									<settlement>Orlando</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2022-05-17">17 May 2022</date>
						</imprint>
					</monogr>
					<idno type="MD5">66FDD65381C05DB6632ACD139465D793</idno>
					<idno type="DOI">10.1182/blood-2016-01-</idno>
					<note type="submission">Submitted January 25, 2016; accepted June 3, 2016. Prepublished online as</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:22+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>We present comprehensive information on genetic driver events in a uniformly treated cohort of 664 adult AML patients aged 18 to 86 years.</s></p><p><s>• Mutations in NPM1, FLT3, CEBPA, TP53, and, in patients ,60 years, DNMT3A and RUNX1, are the most important molecular risk factors in AML.</s></p><p><s>The clinical and prognostic relevance of many recently identified driver gene mutations in adult acute myeloid leukemia (AML) is poorly defined.</s><s>We sequenced the coding regions or hotspot areas of 68 recurrently mutated genes in a cohort of 664 patients aged 18 to 86 years treated on 2 phase 3 trials of the German AML Cooperative Group (AMLCG).</s><s>The median number of 4 mutations per patient varied according to cytogenetic subgroup, age, and history of previous hematologic disorder or antineoplastic therapy.</s><s>We found patterns of significantly comutated driver genes suggesting functional synergism.</s><s>Conversely, we identified 8 virtually nonoverlapping patient subgroups, jointly comprising 78% of AML patients, that are defined by mutually exclusive genetic alterations.</s><s>These subgroups, likely representing distinct underlying pathways of leukemogenesis, show widely divergent outcomes.</s><s>Furthermore, we provide detailed information on associations between gene mutations, clinical patient characteristics, and therapeutic outcomes in this large cohort of uniformly treated AML patients.</s><s>In multivariate analyses including a comprehensive set of molecular and clinical variables, we identified DNMT3A and RUNX1 mutations as important predictors of shorter overall survival (OS) in AML patients &lt;60 years, and particularly in those with intermediate-risk cytogenetics.</s><s>NPM1 mutations in the absence of FLT3-ITD, mutated TP53, and biallelic CEBPA mutations were identified as important molecular prognosticators of OS irrespective of patient age.</s><s>In summary, our study provides a comprehensive overview of the spectrum, clinical associations, and prognostic relevance of recurrent driver gene mutations in a large cohort representing a broad spectrum and age range of intensively treated AML patients.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>2]<ref type="bibr" target="#b2">[3]</ref> The Cancer Genome Atlas (TCGA) consortium studied 200 AML patients by wholegenome or whole-exome sequencing (WGS/WES), and identified 23 genes as "significantly mutated" at a higher-than-expected frequency. <ref type="bibr" target="#b3">4</ref></s><s>Although the functional consequences of many novel recurrent genetic alterations are not yet fully understood, these mutations may become clinically useful molecular markers for diagnosis, prognostication, prediction of treatment response, or disease monitoring.</s><s>Furthermore, defining the spectrum and patterns of driver gene mutations in AML patients is an important step to identify relevant targets for new treatment approaches.</s><s>Simultaneously, the increasing number of genes known to be mutated at intermediate or low frequencies leads to a complex interplay of genetic changes that can only be analyzed in sufficiently large cohorts.</s><s>Therefore, we set out to comprehensively characterize the spectrum and clinical relevance of recurrent driver gene mutations in a large, well-characterized, and homogenously treated group of AML patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subjects and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>We studied 664 previously untreated AML patients who received intensive induction chemotherapy on 2 randomized multicenter phase 3 trials of the German AML Cooperative Group (AMLCG) between 1999 and 2012 (AMLCG-1999, ClinicalTrials.gov</s><s>6]<ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b8">[8]</ref> Treatment regimens are described in the supplemental material, available on the Blood Web site.</s><s>Patients were included in this study if a suitable bone marrow (BM) or peripheral blood (PB) specimen was available.</s><s>The diagnosis of AML was based on World Health Organization (WHO) criteria.</s><s>Cytogenetic risk groups were defined according to the Medical Research Council (MRC) classification. <ref type="bibr" target="#b9">9</ref></s><s>All study protocols were in accordance with the Declaration of Helsinki and approved by the institutional review boards of the participating centers.</s><s>All patients provided written informed consent for inclusion on the clinical trial and genetic analyses.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Targeted sequencing</head><p><s>We studied 68 genes recurrently mutated in myeloid malignancies (supplemental Tables <ref type="table" target="#tab_3">1 and 2</ref>).</s><s>Mononuclear cells were enriched from pretreatment BM or PB by Ficoll density gradient centrifugation.</s><s>We sequenced the entire coding sequences of 37 genes and recurrently mutated regions <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b10">10</ref> in 31 genes, using a custom amplicon-based targeted enrichment assay (Haloplex, Agilent, Boeblingen, Germany) and an Illumina MiSeq instrument (Illumina, San Diego, CA).</s><s>Criteria used to differentiate leukemia-associated driver mutations from germline variants are detailed in the supplemental Methods and in supplemental Figure <ref type="figure">1</ref>.</s><s>Mutations in NPM1 and CEBPA, FLT3 internal tandem duplications (FLT3-ITD), and KMT2A (formerly MLL) partial tandem duplications (KMT2A-PTD) were also tested using standard methods. <ref type="bibr" target="#b11">11,</ref><ref type="bibr" target="#b12">12</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>We studied associations between different gene mutations and between gene mutations and other patient characteristics, using Fisher's exact test for categorical and the Wilcoxon rank-sum test for continuous variables, with adjustment for multiple testing using the Benjamini-Hochberg method.</s><s>Analyses of treatment outcomes used commonly accepted definitions of complete remission (CR), relapse-free survival (RFS), and overall survival (OS) (supplemental Methods). <ref type="bibr" target="#b13">13</ref></s><s>For survival end points, P values were calculated from the Cox proportional hazards model stratified for the trial arm, using the Wald test.</s><s>Multivariate models were used to integrate known clinical and genetic risk factors and potential confounders (supplemental Methods).</s><s>To account for baseline differences (supplemental Table <ref type="table">3</ref>) and different recruitment periods of the 2 clinical trial cohorts, all outcome analyses were adjusted for trial and treatment arm.</s><s>Statistical analyses were performed using R version 3.2.2</s><s>(R Foundation for Statistical Computing, Vienna, Austria).</s><s>Mutation data were deposited in the Catalogue of Somatic Mutations in Cancer, study reference COSP41536 (http://cancer.</s><s>sanger.ac.uk/cancergenome/projects/cosmic/).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Spectrum of driver mutations in adult AML</head><p><s>The median age of the 664 patients was 57 years (range, 18-86).</s><s>Other baseline characteristics are listed in Table <ref type="table" target="#tab_0">1</ref>. <ref type="bibr" target="#b14">14</ref></s><s>The mean sequencing coverage of the target region across all samples was 430-fold, and, on average, 96% of the target region was covered at .303.</s><s>We identified a total of 2395 driver gene mutations in 59 different genes (supplemental Table <ref type="table">4A</ref>).</s><s>Forty-eight genes were recurrently mutated, 35 genes were mutated in .1% of patients, and 10 genes were mutated in .10%</s><s>(Figure <ref type="figure">1A</ref>).</s><s>Patients aged $60 years, representing 43% of the entire cohort, more commonly carried mutations in RUNX1, TET2, IDH2, SRSF2, TP53, BCOR, and SF3B1, and less often had mutations in WT1 compared with those ,60 years (supplemental Figure <ref type="figure">2</ref>).</s></p><p><s>At least 1 driver mutation was identified in 97% of patients (646/ 664).</s><s>Of the remaining 18 patients, 15 had a recurrent balanced chromosomal translocation, resulting in a known fusion transcript.</s><s>Thus, $1 molecularly defined driver lesion was detected in 99.5% of patients.</s><s>The median number of mutations per patient was 4 (range, 0-10; supplemental Figure <ref type="figure" target="#fig_5">3</ref>), and the median number of mutated genes was 3 (range, 0-9).</s><s>The number of mutated driver genes increased with age (Figure <ref type="figure">1B</ref>; P , .001 for association with age as a continuous variable).</s><s>Patients with MRC intermediate-risk cytogenetics had a higher number of mutated driver genes (median, 4) than in those with favorable or adverse cytogenetics (median, 1 and 2 mutated genes, respectively) (Figure <ref type="figure">1C</ref>).</s><s>Finally, patients with secondary AML after an antecedent hematologic disorder (sAML) had more, and patients with treatment-related AML (tAML) had fewer mutations in genes covered by our panel, compared with those with de novo AML (Figure <ref type="figure">1D</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Differences in variant allele frequencies between driver genes</head><p><s>The median variant allele frequency (VAF) of driver gene mutations was 0.36, significantly lower than the VAFs of heterozygous germline polymorphisms (median, 0.50; supplemental Figure <ref type="figure" target="#fig_7">4</ref>).</s><s>Figure <ref type="figure">2</ref> illustrates the spectrum of copy number-adjusted VAFs observed for genes mutated in $20 patients.</s><s>Mutations in some genes including TP53, IDH2, DNMT3A, CEBPA, TET2, and NPM1 and balanced chromosomal rearrangements involving KMT2A or the core-bindingfactor (CBF) genes had a median VAF slightly below 0.5, compatible with heterozygous mutations present in most cells in the specimen.</s><s>In contrast, mutations in other genes showed considerably lower allele frequencies, indicating they were often present only in a subpopulation of the sequenced cells.</s><s>Of note, 5 of the 6 genes with the lowest median VAFs (FLT3, KIT, NRAS, KRAS, and PTPN11) are involved in growth-factor signaling, suggesting that alterations in these pathways are often acquired relatively late during the evolution of the leukemic clone.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Association of driver gene mutations with clinical characteristics and cytogenetics</head><p><s>We studied associations of driver gene mutations occurring in $20 patients with baseline clinical characteristics, cytogenetic alterations, and other gene mutations (Figure <ref type="figure" target="#fig_5">3</ref> and supplemental Table 5A-C).</s><s>NPM1 and DNMT3A mutations were more common, and mutations in RUNX1, SRSF2, ASXL1, STAG2, and BCOR less common in women compared with men (multiple testing-adjusted q , .01; Figure <ref type="figure" target="#fig_5">3A</ref>).</s><s>FLT3-ITD and NPM1 mutations were associated with higher leukocyte counts and higher BM blast percentages.</s><s>Mutations in RUNX1, SRSF2, ASXL1, STAG2, U2AF1, and PTPN11 tended to be more frequent in sAML compared with de novo AML, whereas TP53 mutations were more common in patients with tAML.</s><s>However, none of these associations between individual gene mutations and sAML/tAML was significant at q , .01, and no single mutation was highly specific for sAML or tAML in our cohort.</s></p><p><s>Mutations in NPM1, DNMT3A, FLT3-ITD, IDH1, IDH2, and single (monoallelic) or double (biallelic) CEBPA mutations mostly occurred in patients with normal cytogenetics (Figure <ref type="figure" target="#fig_5">3B</ref>).</s><s>KIT mutations strongly associated with CBF translocations, whereas many other gene mutations were rare or absent in this cytogenetic subset.</s><s>TP53 mutations were closely linked to complex karyotypes, and KRAS mutations associated with KMT2A (MLL) translocations.</s><s>Finally, RUNX1 mutations were enriched in patients with MRC intermediate-risk abnormal karyotypes, a finding partly driven by the known association between trisomy 13 and RUNX1 mutations. <ref type="bibr" target="#b15">15</ref></s><s>tterns of co-occurrence and mutual exclusivity between driver gene mutations When we investigated co-occurrence and mutual exclusivity of driver gene mutations, we found significant (q , .01)</s><s>associations between mutated NPM1 and mutations in DNMT3A, FLT3, and RAD21, and between mutated DNMT3A and FLT3-ITD, IDH1, IDH2, and KMT2A-PTD mutations (Figure <ref type="figure" target="#fig_5">3C</ref> and supplemental Table <ref type="table">5C</ref>).</s><s>RUNX1, SRSF2, ASXL1, STAG2, and BCOR formed a separate cluster of genes that were frequently comutated.</s><s>Strong pairwise associations were also observed between IDH2 and SRSF2, RUNX1 and SF3B1, and double CEBPA and GATA2 mutations.</s></p><p><s>Conversely, certain genetic alterations rarely coexisted in the same patient.</s><s>We used mutually exclusive gene set analysis (MEGSA) <ref type="bibr" target="#b16">16</ref> to identify subsets of patients defined by mutually exclusive genetic alterations (supplemental Methods and Results).</s><s>This analysis revealed 8 distinct and almost nonoverlapping subgroups, namely patients with CBF translocations (RUNX1-RUNX1T1 or CBFB-MYH11), GATA2-MECOM or DEK-NUP214 rearrangements, balanced rearrangements involving KMT2A, double CEBPA mutations, or mutations in TP53, NPM1, or RUNX1 (Figure <ref type="figure" target="#fig_7">4A</ref>).</s><s>Of the 664 patients, 503 (76%) had exactly one of these lesions.</s><s>Only 16 patients (2.4%) carried more than one of these changes, and 145 patients (22%) did not harbor any of the aforementioned genetic alterations and thus could not be assigned to one of the clusters.</s><s>The 8 genetically defined subgroups also showed widely divergent outcomes (Figure <ref type="figure" target="#fig_7">4B-C</ref>)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Driver mutations and survival</head><p><s>We studied the associations of driver mutations found in $20 patients ($3%) with treatment outcomes.</s><s>The median OS of our patient cohort was 17.8 months, and the median follow-up for survivors was 58 months.</s><s>Univariate analyses of gene mutations and OS are reported in supplemental Table <ref type="table">6</ref>.</s><s>Patients with mutated NPM1, particularly in the absence of FLT3-ITD, and those with double CEBPA mutations had relatively favorable OS, whereas survival was significantly shorter for patients carrying mutations in DNMT3A, RUNX1, ASXL1, SRSF2, TP53, BCOR, U2AF1, or SF3B1 (supplemental Figure <ref type="figure" target="#fig_8">5</ref>).</s><s>However, these analyses may be biased because some gene mutations tended to co-occur, or showed associations with other prognostic markers including age and cytogenetics.</s></p><p><s>To account for the complex interrelations between gene mutations and other known risk factors, we constructed multivariate models.</s><s>Because the frequency of several gene mutations differed between younger (,60 years) and older ($60 years) patients, and treatment intensity was higher in younger patients, we also tested for interactions between each individual gene mutation and age.</s><s>In a multivariate model for OS (Table <ref type="table" target="#tab_3">2</ref>), age ,60 years, favorable cytogenetics, mutated NPM1 in the absence of FLT3-ITD, and, in trend, double CEBPA mutations associated with longer OS.</s><s>The prognostic impact of DNMT3A and RUNX1 mutations differed *Modified ELN classification designates the ELN reporting system for genetic alterations <ref type="bibr" target="#b14">14</ref> ; however only patients with double, and not those with single, CEBPA mutations were classified as "favorable."</s></p><p><s>significantly between younger and older patients.</s><s>Both mutations were associated with inferior OS only among younger, but not among older patients.</s><s>Therapy-related AML, decreased performance status, higher leukocyte counts, adverse cytogenetic changes, and TP53 mutations all were associated with shorter OS regardless of age group.</s></p><p><s>Univariate analyses of associations between gene mutations and achievement of CR and RFS are reported in supplemental Tables <ref type="table">7 and 8</ref>, and multivariate analyses of factors related to achievement of CR, RFS, and RFS censored at the time of allogeneic transplantation are shown in supplemental Tables 9-11.</s><s>Similar to the OS model, the multivariate model for CR showed interactions between age group and DNMT3A and RUNX1 mutations, which were associated with lower chances of reaching a remission only among younger patients (supplemental Results).</s><s>Mutations in both genes were also linked to shorter RFS, and no interactions with age group were observed for this end point.</s></p><formula xml:id="formula_0">P &lt; .001 0 FLT3 39% NPM1 33% DNMT3A 31% NRAS 22% RUNX1 15% TET2 15% IDH2 14% WT1 13% ASXL1 11% PTPN11 10% SRSF2 10% TP53 9% CEBPA 8% IDH1 7% BCOR 7% KMT2A-PTD 6% KRAS 6% SRAG2 6% RAD21 5% KIT 4% U2AF1 4% GATA2 4% EZH2 4% SF3B1 3% SMC3 3% ETV6 2% BCORL1 2% PHF6 2% KDM6A 2% CSF3R 2% SMC1A 2% miR142 2% CBL 2% HNRNPK 1% ZRSR2 1% JAK2 1% 0.1</formula><p><s>Fraction of pts. with mutation Prognostic impact of gene mutations in defined age groups and cytogenetic subsets</s></p><p><s>Mutations in certain genes were closely associated with defined, prognostically distinct cytogenetic subgroups.</s><s>Furthermore, multivariate analyses revealed that the impact of some mutations depends on patient age.</s><s>To facilitate interpretation of these results and visualize the combined effects of co-occurring gene mutations on survival, we analyzed patient subsets stratified according to age and cytogenetics.</s><s>The 3 most common driver mutations in our cohort were strongly enriched in patients with intermediate-risk karyotypes.</s><s>NPM1, DNMT3A, and FLT3-ITD mutations occurred in 47% (212/452), 40% (181/452), and 39% (175/452) of MRC intermediaterisk patients, respectively.</s><s>Conversely, 97% of NPM1-mutated patients, 88% of DNMT3A-mutated patients, and 92% of FLT3-ITD-positive patients had intermediate-risk cytogenetics.</s><s>Therefore, we examined the interplay of these mutations with regard to OS in the MRC intermediate-risk patient subset.</s><s>DNMT3A and NPM1 mutations were closely associated in this subgroup (73% of DNMT3A-mutated patients also had mutated NPM1), yet their prognostic relevance was discordant.</s><s>DNMT3A mutations associated with inferior OS among patients ,60 years, but not among older patients (Figure <ref type="figure" target="#fig_8">5A-B</ref>).</s><s>Of note, no survival differences were observed between DNMT3A codon R882 and other DNMT3A mutations (data not shown). <ref type="bibr" target="#b17">17</ref></s><s>On the other hand, NPM1 mutations associated with favorable OS only among older patients (Figure <ref type="figure" target="#fig_8">5C-D</ref>).</s><s>When both mutations were analyzed jointly, DNMT3A mutations remained an unfavorable prognostic factor in younger patients, and NPM1 mutations associated with favorable OS among older patients (Figure <ref type="figure" target="#fig_8">5E-F</ref>).</s><s>Although there was no statistically significant interaction between the 2 mutations, patients with mutated NPM1 and wild-type DNMT3A had the most favorable outcomes in both age groups.</s></p><p><s>Patients with mutated NPM1 in the absence FLT3-ITD reportedly have favorable outcomes relative to all remaining patients (ie, those with wild-type NPM1 and/or FLT3-ITD), a finding that was confirmed in our cohort (supplemental Figure <ref type="figure" target="#fig_9">6</ref>).</s><s>When DNMT3A mutations were studied in conjunction with the combined NPM1/FLT3-ITD genotype, they again associated with significantly shorter OS among younger, but not among older, MRC intermediate-risk patients (Figure <ref type="figure" target="#fig_9">6A-B</ref>).</s></p><p><s>RUNX1 mutations most commonly occurred in patients with intermediate-risk or noncomplex adverse cytogenetics (prevalence, 17% and 22%, respectively).</s><s>In MRC intermediate-risk patients, they were mutually exclusive with NPM1 mutations and, consequently, with the favorable NPM1-mutated, FLT3-ITD-negative genotype.</s><s>RUNX1 mutations associated with shorter OS among younger, and in trend also among older, intermediate-risk patients (Figure <ref type="figure" target="#fig_9">6C-D</ref>).</s><s>Supplemental Figure <ref type="figure">7</ref> illustrates the diversity of outcomes observed among patients with intermediate-risk cytogenetics, depending on age and NPM1, FLT3-ITD, DNMT3A, and RUNX1 mutations status.</s><s>In patients with noncomplex adverse cytogenetics, RUNX1 mutation status did not affect outcomes (not shown).</s><s>KIT mutations occurred in 26% (17/65) of patients with CBF rearrangements and did not associate with CR rate, RFS, or OS.</s><s>Finally, TP53 mutations were present in 45% (52/116) of patients with adverse cytogenetics, including 70% (50/71) of those with complex karyotypes, but in only 1.5% (8/539) of patients with nonadverse karyotypes.</s><s>TP53-mutated patients had significantly shorter OS compared with patients with complex karyotypes or noncomplex adverse cytogenetics without TP53 mutations (Figure <ref type="figure">7</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Our study presents comprehensive information on the incidence, patterns of comutation, clinical correlations, and prognostic relevance of mutations in 68 recurrently mutated genes in adult AML.</s><s>9]<ref type="bibr" target="#b20">[20]</ref> Further strengths of our study include the fact that all patients received comparable treatment on 2 consecutive phase 3 trials, and the long duration of follow-up.</s><s>At least one genetic driver event was identified in .99% of patients when mutations and balanced translocations were combined.</s><s>As reported in previous studies, patients with favorable or unfavorable abnormal cytogenetics, and particularly those with balanced translocations, had a lower number of additional gene mutations compared with those with cytogenetically normal AML or intermediate-risk abnormalities. <ref type="bibr" target="#b19">19</ref></s><s>Fusion genes seem to be strong oncogenic drivers requiring relatively few cooperating events.</s><s>Patients with sAML had a larger number of mutated genes compared to de novo disease, possibly reflecting the stepwise gain of mutations during the evolution of   myelodysplastic syndromes (MDS) or myeloproliferative neoplasms to AML. <ref type="bibr">21,</ref><ref type="bibr" target="#b22">22</ref> The number of driver gene mutations increased with age, even after adjustment for the higher proportion of sAML and the lower incidence of CBF translocations in older patients (data not shown).</s><s>Older patients also were more likely to carry alterations in specific genes including TET2, RUNX1, and ASXL1, as previously reported, <ref type="bibr" target="#b23">[23]</ref><ref type="bibr" target="#b24">[24]</ref><ref type="bibr" target="#b25">[25]</ref><ref type="bibr" target="#b26">[26]</ref><ref type="bibr" target="#b27">[27]</ref><ref type="bibr" target="#b28">[28]</ref> and SRSF2, genes that have recently been implicated in age-related clonal hematopoiesis. <ref type="bibr" target="#b29">29</ref></s><s>These data contribute to our understanding of differences in AML biology between younger and older patients.</s><s>Coleman Lindsley and colleagues recently reported that mutations in 8 different genes are highly specific for sAML, based on a comparison of rigorously selected sAML and de novo AML patients. <ref type="bibr" target="#b22">22</ref></s><s>In our cohort, we only identified a modest association between clinically reported sAML and mutations in 4 of these 629 patients were included in the multivariate model, whereas 35 patients (5%) were excluded because of missing data.</s><s>Gene mutations were included in the multivariate model if they were detected in at least 20 patients and had a univariate P value for OS, not adjusted for multiple comparisons, of #.10.</s><s>The model was stratified for trial arm.</s><s>No variable selection or elimination technique was applied, and all variables were retained in the final model.</s><s>Tests for interaction with age group (,60 y vs $60 y) were performed for each variable.</s></p><formula xml:id="formula_1">T P 5 3 I D H 2 K M T 2 A t r a n s l o c a t i o n D N M T 3 A C E B P A T E T 2 E Z H 2 N P M 1 i n v ( 1 6 ) U 2 A F 1 t ( 8 ; 2 1 ) S F 3 B 1 S R S F 2 R U N X 1 S T A G 2 R A D 2 1 G A T A 2 I D H 1 W T 1 B C O R S M C 3 K I T A S X L 1 K R A S N R A S F</formula><formula xml:id="formula_2">F L T 3 -T K D R A D 2 1 K I T P T P N 1 1 T E T 2 m o C E B P A S T A G 2 B C O R E Z H 2 N R A S K R A S S F 3 B 1 W T 1 G A T A 2 T P 5 3 b iC E B P A U 2 A F 1 A S X L 1 S R S F 2 R U N X 1 S M C 3 K M T</formula><formula xml:id="formula_3">F L T 3 -T K D R A D 2 1 K I T P T P N 1 1 T E T 2 m o C E B P A S T A G 2 B C O R E Z H 2 N R A S K R A S S F 3 B 1 W T 1 G A T A 2 T P 5 3 b iC E B P A U 2 A F 1 A S X L 1 S R S F 2 R U N X 1 S M C 3 K M T 2 A -P T D Bone marrow blasts N P M 1 D N M T 3 A F L T 3 -I T D I D H 1 I D H 2 F L T 3 -T K D R A D 2 1 K I T P T P N 1 1 T E T 2 m o C E B P A S T A G 2 B C O R E Z H 2 N R A S K R A S S F 3 B 1 W T 1 G A T A 2 b iC E B P A U 2 A F 1 A S X L 1 S R S F 2 R U N X 1 S M C 3 K M T</formula><p><s>*The P value for the interaction between DNMT3A mutation status and age group was .018.</s><s>†The P value for the interaction between RUNX1 mutation status and age group was .015.</s></p><p><s>genes, namely SRSF2, ASXL1, STAG2, and U2AF1.</s><s>Of note, Coleman-Lindsley and coworkers also found secondary-type mutations in one third of patients in an unselected older cohort with clinically defined de novo AML.</s><s>Emerging data suggest that age-related clonal hematopoiesis, clonal cytopenias of undetermined significance, and MDS form a spectrum of related conditions. <ref type="bibr" target="#b30">30</ref></s><s>Thus, some of the "de novo" AML patients in our report and in the unselected patient cohort studied by Coleman Lindsley may in fact have had preexisting clonal hematopoiesis or undiagnosed MDS.</s><s>It remains to be determined whether a genetic definition of "secondarytype" AML is more relevant with regard to outcomes than an sAML diagnosis based on clinical history.</s><s>Our findings regarding the mutational landscape of adult AML are largely consistent with the TCGA consortium's WES and WGS data, with FLT3, NPM1, and DNMT3A identified as the most commonly mutated genes. <ref type="bibr" target="#b3">4</ref></s><s>We noted a higher prevalence of NRAS and KRAS mutations (26%) compared with the TCGA cohort (12%), a discrepancy potentially explained by the often low VAF of these mutations and the deeper sequencing coverage achieved by our targeted sequencing approach.</s><s>Overall, 21% of driver mutations in our study had VAFs ,10%, and such variants would likely be missed by conventional Sanger sequencing and standard WES/WGS approaches.</s><s>A targeted NGS study from the Japan Acute Leukemia Study Group on 198 patients aged #65 years found only 6 genes (FLT3, NPM1, DNMT3A, CEBPA, KIT, and NRAS) mutated in .10%. <ref type="bibr" target="#b19">19</ref></s><s>The low frequency of RUNX1 and TET2 and the relatively high frequency of CEBPA and KIT mutations in the Japanese cohort may be a result of its younger age range.</s><s>Mutations in NPM1 (19.2%) and DNMT3A (16%) also were found more rarely compared with our study and other cohorts from Europe and the US, <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b20">20,</ref><ref type="bibr" target="#b31">31</ref> suggesting that ethnicity may affect the mutation spectrum in AML.</s></p><p><s>NGS techniques allow estimating the proportion of cells in a specimen carrying a somatic mutation based on its allele frequency.</s><s>We observed that mutations in some genes, including the epigenetic modifiers DNMT3A, TET2, and IDH2, frequently had VAFs close to 50%.</s><s>This indicates they were usually present in a large majority of cells, consistent with the concept that these mutations constitute early, and potentially initiating, events during leukemogenesis. <ref type="bibr" target="#b32">32,</ref><ref type="bibr" target="#b33">33</ref></s><s>On the other hand, activating mutations in growth factor signaling pathways (eg, FLT3, KIT, NRAS, and KRAS mutations) commonly had lower  VAFs.</s><s>These changes apparently occur relatively late during the evolution of the malignant clone, a conclusion supported by analyses of paired diagnosis and relapse samples showing that FLT3 and RAS mutations are frequently lost during disease progression. <ref type="bibr" target="#b34">34</ref></s><s>We used VAFs corrected for copy number alterations to obtain a measure of the fraction of cells carrying each variant.</s><s>Our assay did not allow us to detect possible copy-neutral loss of heterozygosity, yet this seems to be a relatively rare phenomenon in AML. <ref type="bibr" target="#b35">35</ref></s><s>Although the number of somatic variants identified through targeted sequencing is not sufficient to infer the precise clonal architecture in individual patients, our findings have implications for the development of targeted therapies aimed at eradicating the malignant "founder clone."</s></p><p><s>Our study confirms previously reported associations of co-occurring driver mutations (eg, between mutations in DNMT3A, NPM1 and FLT3, 4 between double CEBPA and GATA2 mutations, <ref type="bibr" target="#b36">36</ref> and between RUNX1 and ASXL1 mutations). <ref type="bibr" target="#b24">24</ref></s><s>Contrary to a recently published study suggesting a link between CSF3R p.T618I and biallelic CEBPA mutations, we found only one CSF3R mutation among 27 CEBPA double-mutated patients. <ref type="bibr" target="#b37">37</ref></s><s>We also identified associations that, to our knowledge, have not been described in AML before, including frequent comutation of SRSF2 with RUNX1 and IDH2, as previously reported in MDS. <ref type="bibr" target="#b38">38,</ref><ref type="bibr" target="#b39">39</ref></s><s>Frequent co-occurrence of mutations implies functional synergism, and our findings may inform further studies aiming to understand the underlying functional interactions.</s></p><p><s>Conversely, we also identified mutations that rarely coexist in the same patient, suggesting these alterations might have antagonistic or synthetic lethal effects.</s><s>In particular, we identified a set of 8 genetic alterations that collectively occur in .75% of AML patients but show almost complete mutual exclusivity.</s><s>The nonoverlapping, clinically distinct subgroups defined by these alterations likely correspond to different, and apparently incompatible, underlying pathways of leukemogenesis.</s><s>Our data also support the inclusion of AML with RUNX1 or biallelic CEBPA mutations as separate entities in the upcoming revision of the WHO classification. <ref type="bibr" target="#b40">40</ref></s><s>ur large and uniformly treated cohort allowed us to comprehensively study the prognostic relevance of recurrent gene mutations.</s><s>In multivariate analyses including molecular markers, cytogenetics and other potential risk factors and also testing for interactions with patient age, we found that NPM1 mutations in the absence of FLT3-ITD and, in trend, double CEBPA mutations associated with favorable OS, and patients with mutated TP53 had shorter OS, regardless of age.</s><s>DNMT3A and RUNX1 mutations were linked to shorter OS only in patients ,60 years, a finding that can at least partially be explained by the lower odds of reaching a CR for younger patients with these mutations.</s></p><p><s>2]<ref type="bibr" target="#b43">[43]</ref><ref type="bibr" target="#b44">[44]</ref> We analyzed a comprehensive panel of known driver genes in patients across a broad age range and encompassing all cytogenetic subsets except acute promyelocytic leukemia.</s><s>Therefore, our results provide strong evidence that TP53 and, in younger patients, DNMT3A and RUNX1, gene mutations are among the most relevant molecular risk factors in intensively treated adult AML.</s><s>We confirm the importance of NPM1, FLT3-ITD, and CEBPA mutations that are already recognized in international guidelines. <ref type="bibr" target="#b45">45</ref></s><s>Despite the prognostic information provided by molecular markers, cytogenetics remained an important risk factor in multivariate analyses, and gene mutations were often linked to specific cytogenetic subsets.</s><s>Subgroup analyses in patients stratified according to age group and cytogenetics illustrate that DNMT3A and RUNX1 mutations can refine risk stratification, particularly for younger patients with intermediate-risk karyotypes.</s><s>Within the adverse cytogenetic risk group, TP53 mutations define a subset of patients with particularly dismal outcomes.</s></p><p><s>Recently, two studies suggested that a higher number of driver gene mutations may be an adverse prognostic factor in MDS and AML. <ref type="bibr" target="#b39">39,</ref><ref type="bibr" target="#b45">45</ref></s><s>Complex molecular genetic abnormalities, defined as $3 mutations in a 28-gene panel, were associated with shorter OS in a Japanese de novo AML cohort. <ref type="bibr" target="#b45">45</ref></s><s>We found that patients with .5 mutated genes had inferior survival in univariate analyses (supplemental Results), but not in multivariate models accounting for individual gene mutations and cytogenetics.</s><s>Thus, the prognostic impact of specific driver gene mutations apparently outweighs the impact of total mutation number.</s></p><p><s>Integrating the prognostic information provided by gene mutations, cytogenetics, and other markers into clinically applicable risk stratification algorithms is an important yet challenging task.</s><s>Several groups have proposed novel risk stratification schemes for AML based on gene mutations alone or in combination with other risk factors. <ref type="bibr" target="#b19">19,</ref><ref type="bibr" target="#b20">20,</ref><ref type="bibr" target="#b44">44</ref></s><s>Compared with our work, these studies focused on smaller sets of commonly mutated genes.</s><s>Our cohort size was not sufficient to establish and independently validate another new molecular risk classification encompassing not only high-but also intermediate-frequency markers.</s><s>Integration of the accumulating information on genetic risk factors in AML into clinically applicable algorithms should occur through collaboration of multiple study groups to increase sample size and validity.</s></p><p><s>One limitation of our study is that we focused on a predefined set of recurrently mutated genes, and not the entire coding sequence was analyzed for genes with well-defined "hotspots."</s><s>However, our assay covered 99% of the mutations in the 68 target genes that were found in the TCGA cohort.</s><s>WES or WGS remain the preferred approaches for comprehensive mutation analyses.</s><s>However, genome-wide somatic variant calling requires matched germline DNA, and suitable nonleukemic tissue was not available for our patients.</s></p><p><s>In summary, our study offers a detailed survey of recurrent driver gene mutations in one of the largest, well-characterized, and uniformly treated adult AML cohorts analyzed so far.</s><s>We provide detailed insights into patterns of gene mutations, their clinical correlations, and their prognostic relevance.</s><s>We hope our work will serve as an important reference for future research on AML pathogenesis, and as a starting Complex vs. non-complex karyotype: HR, 1.37; P = .24</s><s>TP53 mut vs. TP53 wt : HR, 3.22; P &lt; .001</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>5 Figure 1 .</head><label>51</label><figDesc><div><p><s>Figure 1.</s><s>Overview of driver gene mutations identified by targeted sequencing in 664 AML patients.</s><s>(A) Histogram showing the frequency of driver gene mutations detected in .1% of patients.</s><s>Bars are colored according to the functional category assigned to each driver gene.</s><s>(B) Number of mutated driver genes per patient, according to age category (,40 years, n 5 112; 40-59 years, n 5 264; $60 years, n 5 288).</s><s>(C) Number of mutated driver genes per patient, according to MRC cytogenetic risk category (favorable, n 5 65; intermediate, n 5 452; adverse, n 5 129).</s><s>(D) Number of mutated driver genes per patient for patients with de novo AML (n 5 570) compared with sAML (n 5 59) or tAML (n 5 35).</s><s>P values in (B-D) were calculated by the Kruskal-Wallis test, without adjustment for multiple testing.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Associations between driver gene mutations, cytogenetics, and patient characteristics.</s><s>Associations were studied for driver gene mutations found in $20 patients, and statistical significance was assessed using the Fisher exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables, with adjustment for multiple testing using the Benjamini-Hochberg method.</s><s>Only those pairings that were significant at an adjusted q , .1 are shown.</s><s>The odds ratio of the association is color coded, and the significance level is indicated by the symbol in each field.</s><s>Orange and red colors indicate a positive association (ie, 2 characteristics that frequently occurred together in the same patient, or for the association between a mutation and a continuous variable, a higher value in those carrying the mutation).</s><s>Blue colors indicate a negative association (ie, 2 characteristics that rarely occurred together in the same patient, or for the association between a mutation and a continuous variable, a lower value in those carrying the mutation).(A)</s><s>Pairwise associations between gene mutations and clinical patient characteristics.</s><s>(B) Pairwise associations between gene mutations and cytogenetic findings.</s><s>(C) Pairwise associations among gene mutations.</s></p></div></figDesc><graphic coords="6,205.07,540.09,172.46,69.02" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Subgroups of AML patients defined by mutually exclusive genetic alterations.</s><s>(A) Heatmap depicting gene mutations and balanced chromosomal translocations in 664 adult AML patients.</s><s>Mutually exclusive gene signature analysis (MEGSA) identified 8 patient clusters (color coded at the top of the figure) based on almost mutually exclusive genetic alterations.</s><s>The CBF rearrangements (RUNX1-RUNX1T1 and CBF-MYH11) were combined into 1 cluster in this analysis.</s><s>The 9 resulting patient subgroups (8 mutually exclusive clusters and 1 subgroup comprising the remaining patients) differ with regard to co-occurring gene mutations and clinical characteristics.</s><s>(B) RFS and (C) OS of the patient subgroups defined by mutually exclusive genetic alterations.</s><s>Subgroups are color coded according to legend at the top of the figure.</s><s>Patients with DEK-NUP214 were not included in both analyses, and patients with GATA2-MECOM were not included in the analysis of RFS, owing to small patient numbers.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head>Figure 5 .</head><label>5</label><figDesc><div><p><s>Figure 5. Survival of patients with MRC intermediate-risk cytogenetics according to age group and DNMT3A and NPM1 mutation status.</s><s>(A) OS for MRC intermediate-risk patients aged ,60 years or (B) aged $60 years, stratified according to DNMT3A mutation status.</s><s>(C) OS for MRC intermediate-risk patients aged ,60 years or (D) aged $60 years, stratified according to NPM1 mutation status.</s><s>(E) OS for MRC intermediate-risk patients aged ,60 years or (F) aged $60 years, stratified according to DNMT3A and NPM1 mutation status.</s><s>P values in (A-D) were calculated from univariate Cox proportional hazards models, and in (E) and (F) from bivariate models, using the Wald test.</s><s>All models were stratified for treatment arm.</s><s>mut, mutated; wt, wild-type.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head>Figure 6 .</head><label>6</label><figDesc><div><p><s>Figure 6.</s><s>Survival of patients with MRC intermediate-risk cytogenetics according to the combined NPM1 and FLT3-ITD mutations status and DNMT3A and RUNX1 mutations.</s><s>(A) OS of MRC intermediate-risk patients aged ,60 years or (B) aged $60 years, stratified according to the combined NPM1/FLT3-ITD genotype and DNMT3A mutations status.</s><s>(C) OS of MRC intermediate-risk patients aged ,60 years or (D) aged $60 years, comparing patients with mutated RUNX1 to RUNX1-wild-type patientswith mutated NPM1 without FLT3-ITD (this prognostically favorable genotype was mutually exclusive with mutated RUNX1, and is thus shown separately), and all remaining patients (ie, wild-type NPM1 and/or FLT3-ITD and wild-type RUNX1).</s><s>P values were calculated from bivariate Cox proportional hazards models stratified for trial arm, using the Wald test.</s><s>mut, mutated; neg, negative; wt, wild-type.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><head></head><label></label><figDesc><div><p><s>Complex karyotype, TP53 wt n = 21 Non-complex adverse, TP53 wt n = 56 TP53 mut n = 52</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_11"><head>Figure</head><label></label><figDesc><div><p><s>Figure 7. Survival of patients with MRC adverse-risk cytogenetics according to TP53 mutation status.</s><s>OS of MRC adverse-risk patients with mutated TP53, compared with patients with wild-type TP53 and complex or noncomplex adverse cytogenetics.</s><s>A complex karyotype was defined as $4 unrelated abnormalities per the MRC classification.</s><s>P values were calculated from a bivariate Cox proportional hazards model stratified for trial arm, using the Wald test.</s><s>mut, mutated; wt, wild-type.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="8,96.38,86.80,399.18,488.41" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Pretreatment patient characteristics</s></p></div></figDesc><table><row><cell></cell><cell>Total cohort,</cell><cell>Younger patients</cell><cell>Older patients</cell></row><row><cell>Variable</cell><cell>N 5 664</cell><cell>(&lt;60 y), N 5 376</cell><cell>( ‡60 y), N 5 288</cell></row><row><cell>Age (y)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell>57</cell><cell>45</cell><cell>67</cell></row><row><cell>Range</cell><cell>18-86</cell><cell>18-59</cell><cell>60-68</cell></row><row><cell>Female gender, n (%)</cell><cell>(50)</cell><cell>203 (54)</cell><cell>127 (44)</cell></row><row><cell>De novo AML</cell><cell>(86)</cell><cell>335 (89)</cell><cell>235 (82)</cell></row><row><cell>Secondary AML</cell><cell>59 (9)</cell><cell>22 (6)</cell><cell>37 (13)</cell></row><row><cell>Therapy-related AML</cell><cell>35 (5)</cell><cell>19 (5)</cell><cell>16 (6)</cell></row><row><cell>ECOG performance</cell><cell></cell><cell></cell><cell></cell></row><row><cell>status, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell>(27)</cell><cell>111 (30)</cell><cell>61 (22)</cell></row><row><cell>1</cell><cell>(48)</cell><cell>175 (47)</cell><cell>138 (49)</cell></row><row><cell>2</cell><cell>(19)</cell><cell>59 (16)</cell><cell>66 (24)</cell></row><row><cell>3</cell><cell>33 (5)</cell><cell>20 (5)</cell><cell>13 (5)</cell></row><row><cell>4</cell><cell>6 (1)</cell><cell>4 (1)</cell><cell>2 (1)</cell></row><row><cell>WBC count, 310 9 /L</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell>23.4</cell><cell>25.7</cell><cell>20.9</cell></row><row><cell>Range</cell><cell>0.1-666</cell><cell>0.1-486</cell><cell>0.5-666</cell></row><row><cell>Hemoglobin, g/dL</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell>9.0</cell><cell>9.0</cell><cell>9.0</cell></row><row><cell>Range</cell><cell>3.5-16.0</cell><cell>3.5-15.6</cell><cell>3.8-16</cell></row><row><cell>Platelet count,</cell><cell></cell><cell></cell><cell></cell></row><row><cell>310 9 /L</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell>53</cell><cell>52</cell><cell>55</cell></row><row><cell>Range</cell><cell>1-1760</cell><cell>1-1760</cell><cell>1-471</cell></row><row><cell>Bone marrow</cell><cell></cell><cell></cell><cell></cell></row><row><cell>blasts, %</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell>80</cell><cell>80</cell><cell>80</cell></row><row><cell>Range</cell><cell>6-100</cell><cell>6-100</cell><cell>9-100</cell></row><row><cell>FAB category, n</cell><cell></cell><cell></cell><cell></cell></row><row><cell>M0</cell><cell>35</cell><cell>16</cell><cell>19</cell></row><row><cell>M1</cell><cell>157</cell><cell>80</cell><cell>77</cell></row><row><cell>M2</cell><cell>178</cell><cell>93</cell><cell>85</cell></row><row><cell>M4</cell><cell>163</cell><cell>107</cell><cell>56</cell></row><row><cell>M5</cell><cell>83</cell><cell>51</cell><cell>32</cell></row><row><cell>M6</cell><cell>19</cell><cell>11</cell><cell>8</cell></row><row><cell>M7</cell><cell>3</cell><cell>3</cell><cell>0</cell></row><row><cell>MRC cytogenetic</cell><cell></cell><cell></cell><cell></cell></row><row><cell>risk category</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Favorable</cell><cell>65 (10)</cell><cell>50 (14)</cell><cell>15 (5)</cell></row><row><cell>Intermediate</cell><cell>(70)</cell><cell>254 (69)</cell><cell>198 (71)</cell></row><row><cell>Adverse</cell><cell>(20)</cell><cell>65 (18)</cell><cell>64 (23)</cell></row><row><cell>Modified ELN</cell><cell></cell><cell></cell><cell></cell></row><row><cell>classification*</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Favorable</cell><cell>(29)</cell><cell>128 (35)</cell><cell>61 (22)</cell></row><row><cell>Intermediate-I</cell><cell>(32)</cell><cell>107 (29)</cell><cell>98 (35)</cell></row><row><cell>Intermediate-II</cell><cell>(18)</cell><cell>62 (17)</cell><cell>57 (21)</cell></row><row><cell>Adverse</cell><cell>(21)</cell><cell>72 (20)</cell><cell>61 (22)</cell></row><row><cell>NPM1-mutated,</cell><cell>(33)</cell><cell>129 (34)</cell><cell>92 (32)</cell></row><row><cell>n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>FLT3-ITD present,</cell><cell>(30)</cell><cell>119 (32)</cell><cell>78 (27)</cell></row><row><cell>n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CEBPA, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Single mutation</cell><cell>25 (4)</cell><cell>13 (3)</cell><cell>12 (4)</cell></row><row><cell>Double mutation</cell><cell>27 (4)</cell><cell>22 (6)</cell><cell>5 (2)</cell></row><row><cell>DNMT3A-mutated,</cell><cell>(31)</cell><cell>108 (29)</cell><cell>101 (35)</cell></row><row><cell>n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>RUNX1-mutated,</cell><cell>(15)</cell><cell>35 (9)</cell><cell>67 (23)</cell></row><row><cell>no. (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>TP53 mutated, n (%)</cell><cell>63 (9)</cell><cell>23 (6)</cell><cell>40 (14)</cell></row></table><note><p><s>ECOG, Eastern Cooperative Oncology Group; ELN, European LeukemiaNet; FAB, French-American-British classification; ITD, internal tandem duplication; MRC, British Medical Research Council.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc><div><p><s>Figure 2. Analysis of variant allele frequencies (VAFs) of different driver gene mutations.The boxplot shows the median, 25th, and 75th percentiles, and minimum and maximum VAF observed across the entire cohort of 664 patients.</s><s>VAFs were adjusted for local copy number.</s><s>Boxes are colored according to the functional category assigned to each driver gene.</s><s>Only mutations found in $20 patients were included.</s><s>The black dashed line marks an allele frequency of 0.5, the expected VAF for a heterozygous variant present in all cells in the specimen.</s><s>Insertions and deletions of $15</s></p></div></figDesc><table><row><cell>Activated signaling</cell><cell>RNA splicing</cell></row><row><cell>DNA methylation</cell><cell>Tumor suppressors</cell></row><row><cell>Transcription factors</cell><cell>Cohesin complex</cell></row><row><cell>Chromatin modifiers</cell><cell>NPM1</cell></row><row><cell></cell><cell>base pairs were excluded, because VAFs for larger</cell></row><row><cell></cell><cell>variants were skewed, possibly because of amplifica-</cell></row><row><cell></cell><cell>tion bias. VAFs for balanced translocations and inversions</cell></row><row><cell></cell><cell>(ie, t(8;21), inv(16) and balanced translocations involving</cell></row><row><cell></cell><cell>the KMT2A locus) were determined by interphase fluo-</cell></row><row><cell></cell><cell>rescence in situ hybridization on $200 nuclei.</cell></row><row><cell></cell><cell>L T 3 P T P N 1 1</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Multivariate analysis for overall survival</s></p></div></figDesc><table /><note><p><s>95% CI, 95% confidence interval; ECOG, Eastern Cooperative Oncology Group; MRC, Medical Research Council; ITD, internal tandem duplication.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head></head><label></label><figDesc><div><p><s>NPM1 mut and FLT3-ITD neg RUNX1 wt n = 56</s></p></div></figDesc><table><row><cell>A</cell><cell></cell><cell cols="7">MRC intermediate risk, age &lt; 60 years</cell><cell>B</cell><cell></cell><cell cols="7">MRC intermediate risk, age ≥ 60 years</cell></row><row><cell></cell><cell></cell><cell cols="4">NPM1 wt and/or FLT3-ITD +</cell><cell cols="3">DNMT3A wt n = 135 DNMT3A mut n = 63</cell><cell></cell><cell></cell><cell cols="4">NPM1 wt and/or FLT3-ITD +</cell><cell cols="3">DNMT3A wt n = 88 DNMT3A mut n = 63</cell></row><row><cell></cell><cell>1.0</cell><cell cols="7">NPM1 mut and FLT3-ITD neg DNMT3A wt n = 23 DNMT3A mut n = 33</cell><cell></cell><cell>1.0</cell><cell cols="7">NPM1 mut and FLT3-ITD neg DNMT3A wt n = 25 DNMT3A mut n = 22</cell></row><row><cell>Overall survival</cell><cell>0.2 0.4 0.6 0.8</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Overall survival</cell><cell>0.2 0.4 0.6 0.8</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>0.0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>0</cell><cell>1</cell><cell>2</cell><cell>3</cell><cell>4</cell><cell>5</cell><cell>6</cell><cell>7</cell><cell>8</cell><cell>0</cell><cell>1</cell><cell>2</cell><cell>3</cell><cell>4</cell><cell>5</cell><cell>6</cell><cell>7</cell><cell>8</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">years</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="8">DNMT3A mut vs. DNMT3A wt : NPM1 mut and FLT3-ITD neg vs. others: HR, 0.54; P = .008 HR, 1.86; P &lt; .001</cell><cell></cell><cell cols="8">DNMT3A mut vs. DNMT3A wt : NPM1 mut and FLT3-ITD neg vs. others: HR, 0.40; P &lt; .001 HR, 0.98; P = .92</cell></row><row><cell>C</cell><cell></cell><cell cols="7">MRC intermediate risk, age &lt; 60 years</cell><cell>D</cell><cell></cell><cell cols="7">MRC intermediate risk, age ≥ 60 years</cell></row><row><cell></cell><cell></cell><cell cols="4">NPM1 wt and/or FLT3-ITD +</cell><cell cols="3">RUNX1 wt n = 173 RUNX1 mut n = 25</cell><cell></cell><cell></cell><cell cols="4">NPM1 wt and/or FLT3-ITD +</cell><cell cols="3">RUNX1 wt n = 100 RUNX1 mut n = 51</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="7">NPM1 mut and FLT3-ITD neg RUNX1 wt n = 47</cell></row><row><cell></cell><cell>1.0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Overall survival</cell><cell>0.4 0.6 0.8</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Overall survival</cell><cell>0.4 0.6 0.8</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>0.2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>0.0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>0</cell><cell>1</cell><cell>2</cell><cell>3</cell><cell>4</cell><cell>5</cell><cell>6</cell><cell>7</cell><cell>8</cell><cell>0</cell><cell>1</cell><cell>2</cell><cell>3</cell><cell>4</cell><cell>5</cell><cell>6</cell><cell>7</cell><cell>8</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">years</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="8">RUNX1 mut vs. RUNX1 wt : NPM1 mut and FLT3-ITD neg vs. others: HR, 0.71; P = .13 HR, 2.22; P = .001</cell><cell></cell><cell cols="8">RUNX1 mut vs. RUNX1 wt : NPM1 mut and FLT3-ITD neg vs. others: HR, 0.45; P = .001 HR, 1.42; P = .06</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head></head><label></label><figDesc><div><p><s>7. Survival of patients with MRC adverse-risk cytogenetics according to TP53 mutation status.</s><s>OS of MRC adverse-risk patients with mutated TP53, compared with patients with wild-type TP53 and complex or noncomplex adverse cytogenetics.</s><s>A complex karyotype was defined as $4 unrelated abnormalities per the MRC classification.</s><s>P values were calculated from a bivariate Cox proportional hazards model stratified for trial arm, using the Wald test.</s><s>mut, mutated; wt, wild-type.</s><s>point for a new, genetically-based disease classification that will contribute to improved risk stratification and, ultimately, better treatment results.</s></p></div></figDesc><table /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Downloaded from http://ashpublications.org/blood/article-pdf/128/5/686/1398120/686.pdf by guest on 17 May 2022</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>The authors thank Thorsten Haferlach, of the Munich Leukemia Laboratory (MLL) for providing patient samples.</s><s>They are grateful to the patients who volunteered to participate in AMLCG clinical trials, and they acknowledge the contributions of physicians and other health care professionals at all participating centers.</s></p><p><s>This</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Conflict-of-interest disclosure: The authors declare no competing financial interests.</s></p><p><s>A complete list of the members of the German Chronic Lymphocytic Leukemia Study Group appears in "Appendix."</s></p><p><s>Correspondence: Klaus H. Metzeler, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilans-Universität, Marchioninistrasse 15, 81377 München, Germany; e-mail: klaus.metzeler@med.uni-muenchen.de.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Appendix: study group members</head><p><s>The members of the German Acute Myeloid Leukemia Cooperative</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Heinecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Sauerland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Görlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Ittel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fuß</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Korsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hennesser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mayr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Grüneisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Possinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Blau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dörken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Maschmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Boewer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Derwahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Englisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Notter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ludwig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Schöndube</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Späth-Schwalbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hesse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Potenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Weh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zumsprekel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Teschendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stechstor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Trenn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wörmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hertenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thomssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Peyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hallek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Staib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Heike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Niederste-Hollenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pielken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hindahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wehmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Heyll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Aul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Giagounidis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Lange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kuhlemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Flaßhove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Karow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fuchs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schlegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kiehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Meckenstock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Haase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Trümper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Griesinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gropp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Depenbusch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Eimermacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schütte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Haak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Braumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Balleisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Lange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schmitz-Hübner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ritter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">R</forename><surname>Link</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fölsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kneba</surname></persName>
		</author>
		<author>
			<persName><surname>Dormann</surname></persName>
		</author>
		<author>
			<persName><surname>Th</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Frieling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Planker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Middeke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gr Ündgens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K.-A</forename><surname>Constantin</surname></persName>
		</author>
		<author>
			<persName><surname>Jost</surname></persName>
		</author>
		<author>
			<persName><surname>Th</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fetscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schmielau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Uppenkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hehlmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lengfelder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schwonzen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Spangenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Graeven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kohl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Heuer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Emmerich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dengler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Schlag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hiddemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nibler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Fleckenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Berdel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Büchner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kienast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mesters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Müller-Tidow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Serve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Krug</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hartlapp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hegge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Peceny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName><surname>Innig</surname></persName>
		</author>
		<author>
			<persName><surname>Th</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Südhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Maschmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">; W</forename><surname>Kreuser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zschille</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Braess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Amler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Korsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hennesser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Witt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kallinich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Oldenkott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ratei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y.-D</forename><surname>Behringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E.-B</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K.-A</forename><surname>Zinngrebe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kreuzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kiehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H.-W</forename><surname>Massenkeil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Lindemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Maciejewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Roemer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nowak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Biersack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schleyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Spiekermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Braess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hentrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Peceney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gaska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Braees</surname></persName>
		</author>
		<author>
			<persName><surname>Schwerdtfeger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<editor>M. Schenk, A. Reichle, R. Andreesen, H. Huff, D. Schönberger, W. Gassmann, T. Gaske, N. Frickhofen, H.-G. Fuhr, W. Augener, W. Brugger, G. Papakonstantinou, U. Kreibich, G. Schott, S. Sommer,</editor>
		<imprint>
			<biblScope unit="volume">456</biblScope>
			<biblScope unit="issue">7218</biblScope>
			<biblScope unit="page" from="66" to="72" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>References 1. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">DNMT3A mutations in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Ley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Walter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="2424" to="2433" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Recurring mutations found by sequencing an acute myeloid leukemia genome</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Mardis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Dooling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1058" to="1066" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia</title>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="2059" to="2074" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Cancer Genome Atlas Research Network</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group</title>
		<author>
			<persName><forename type="first">T</forename><surname>B Üchner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Berdel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Haferlach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="61" to="69" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">T</forename><surname>B Üchner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Berdel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schoch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="2480" to="2489" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">High efficacy and significantly shortened neutropenia of dose-dense S-HAM as compared to standard double induction: first results of a prospective randomized trial (AML-CG</title>
		<author>
			<persName><forename type="first">J</forename><surname>Braess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K-A</forename><surname>Kreuzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Spiekermann</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>abstract</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Abstract 619</title>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">21</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">U</forename><surname>Krug</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Berdel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Gale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1230" to="1236" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials</title>
		<author>
			<persName><forename type="first">D</forename><surname>Grimwade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Hills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Moorman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="354" to="365" />
			<date type="published" when="2010">2010</date>
		</imprint>
		<respStmt>
			<orgName>National Cancer Research Institute Adult Leukaemia Working Group</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">COSMIC: exploring the world&apos;s knowledge of somatic mutations in human cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Forbes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Beare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gunasekaran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="D805" to="D811" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Benthaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mellert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="230" to="239" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)</title>
		<author>
			<persName><forename type="first">F</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hoster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Unterhalt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="5250" to="5253" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Cheson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Kopecky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="4642" to="4649" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet</title>
		<author>
			<persName><forename type="first">H</forename><surname>D Öhner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Estey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Amadori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="453" to="474" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Herold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Metzeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vosberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1304" to="1311" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">MEGSA: A Powerful and Flexible Framework for Analyzing Mutual Exclusivity of Tumor Mutations</title>
		<author>
			<persName><forename type="first">X</forename><surname>Hua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Hyland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hum Genet</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="442" to="455" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Agerelated prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Marcucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Metzeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schwind</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="742" to="750" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Genomic classification and prognosis in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">E</forename><surname>Papaemmanuil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gerstung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="2209" to="2221" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients</title>
		<author>
			<persName><forename type="first">R</forename><surname>Kihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kiyoi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1586" to="1595" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Prognostic relevance of integrated genetic profiling in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Figueroa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1079" to="1089" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">An integrated map of genetic variation from 1,092 human genomes</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Abecasis</surname></persName>
			<affiliation>
				<orgName type="collaboration">Genomes Project Consortium</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Auton</surname></persName>
			<affiliation>
				<orgName type="collaboration">Genomes Project Consortium</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Brooks</surname></persName>
			<affiliation>
				<orgName type="collaboration">Genomes Project Consortium</orgName>
			</affiliation>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">491</biblScope>
			<biblScope unit="issue">7422</biblScope>
			<biblScope unit="page" from="56" to="65" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Acute myeloid leukemia ontogeny is defined by distinct somatic mutations</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Lindsley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Mar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mazzola</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1367" to="1376" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Metzeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Maharry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="6920" to="6929" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Mendler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Maharry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Radmacher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="3109" to="3118" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">I</forename><surname>Gaidzik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schlenk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1364" to="1372" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">I</forename><surname>Gaidzik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Paschka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sp Äth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1350" to="1357" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Metzeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Maharry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Radmacher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1373" to="1381" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>R Ücker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schlenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2114" to="2121" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence</title>
		<author>
			<persName><forename type="first">G</forename><surname>Genovese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Handsaker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="2477" to="2487" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Steensma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bejar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jaiswal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="9" to="16" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Simpson&apos;s Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Gale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lamb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Allen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="2072" to="2083" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Jan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Snyder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Corces-Zimmerman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">149</biblScope>
			<biblScope unit="page" from="149" to="118" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">HALT Pan-Leukemia Gene Panel Consortium. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">I</forename><surname>Shlush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mitchell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">506</biblScope>
			<biblScope unit="issue">7488</biblScope>
			<biblScope unit="page" from="328" to="333" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kr Önke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Teleanu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="100" to="108" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Acquired copy number alterations in adult acute myeloid leukemia genomes</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Payton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Ries</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="issue">31</biblScope>
			<biblScope unit="page" from="12950" to="12955" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Greif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dufour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Konstandin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="395" to="403" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Chemogenomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors</title>
		<author>
			<persName><forename type="first">V-P</forename><surname>Lavall Ée</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Krosl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lemieux</surname></persName>
		</author>
		<idno>10.1182-blood-2016-03-705053</idno>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes</title>
		<author>
			<persName><forename type="first">F</forename><surname>Thol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schlarmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="3578" to="3584" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Clinical and biological implications of driver mutations in myelodysplastic syndromes</title>
		<author>
			<persName><forename type="first">E</forename><surname>Papaemmanuil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gerstung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Malcovati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page">3699</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Arber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Orazi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hasserjian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="2391" to="2405" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">I</forename><surname>Gaidzik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schlenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Paschka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="4769" to="4777" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schlenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Krauter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="1909" to="1918" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity</title>
		<author>
			<persName><forename type="first">E</forename><surname>Taskesen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Corbacioglu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="2469" to="2475" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">A novel hierarchical prognostic model of AML solely based on molecular mutations</title>
		<author>
			<persName><forename type="first">V</forename><surname>Grossmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schnittger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kohlmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="2963" to="2972" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wakita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ueki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="545" to="554" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
